Screening for EGFR Amplifications with a Novel Method and Their Significance for the Outcome of Glioblastoma Patients

摘要: Glioblastoma is a highly aggressive tumour of the central nervous system, characterised by poor prognosis irrespective applied treatment. The aim our study was to analyse whether molecular markers glioblastoma (i.e. TP53 and IDH1 mutations, CDKN2A deletion, EGFR amplification, chromosome 7 polysomy EGFRvIII expression) could be associated with distinct and/or response therapy. Moreover, we describe method which allows for reliable, as well time- cost-effective, screening amplification quantitative Real-Time PCR at DNA level. In clinical data, only patient’s age had prognostic significance (continuous: HR = 1.04; p<0.01). At level, expression better (HR 0.37; p 0.04). Intriguingly, worse outcome in younger patients 3.75; p<0.01) treated radiotherapy 2.71; 0.03). We did not observe any difference between without such Next, related combination homozygous deletion 0.12; 0.01), but poorer 14.88; 0.01). Importantly, results emphasise necessity distinguish both mechanisms increased gene copy number (amplification polysomy). To conclude, although data presented here require validation different groups patients, they strongly advocate consideration characteristics selection